Legend Biotech (NASDAQ:LEGN) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Legend Biotech (NASDAQ:LEGN – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $87.00 price objective on the stock. HC Wainwright also issued estimates for Legend Biotech’s Q1 2024 earnings at ($0.01) EPS and Q3 2024 earnings […]

Related Keywords

United States ,China ,Canada ,American ,Raymond James ,Lazard Asset Management ,Coppell Advisory Solutions ,Legend Biotech Corporation ,Royal Bank ,Bluepath Capital Management ,American International Group Inc ,Cantor Fitzgerald ,Barclays ,Legend Biotech ,Free Report ,Moderate Buy ,Biotech Trading Down ,Get Free Report ,Path Capital Management ,Advisory Solutions ,International Group ,Asset Management ,Biotech Corporation ,Legend Biotech Daily ,Nasdaq Legn ,Legn ,Medical ,Reiterated Rating ,Hc Wainwright ,